InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug...

|By:, SA News Editor

InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be completed until the end of 2012; it had previously forecast enrollment would be completed in Q2. Citing the delay, Jefferies and Leerink Swann cut price targets on the shares.